HCW Biologics Inc. (NASDAQ: HCWB) reported second quarter 2026 revenues of $135,568, a significant increase from $6,550 in the same period last year. The revenue growth was primarily driven by the closing of an exclusive worldwide licensing agreement with Beijing Trimmune Biotech Co., Ltd. for the in vivo rights to HCW11-006, along with associated post-transfer services.

Despite the top-line improvement, the clinical-stage biopharmaceutical company recorded a net loss of $5.2 million for the three months ended June 30, 2026, widening from a $1.9 million loss in Q2 2025. The deterioration in profitability was heavily influenced by non-operating items, specifically a $2.4 million loss resulting from changes in the fair value of warrant liabilities prior to their reclassification to permanent equity.

Financial Performance

The company’s operating expenses showed discipline, with total operating expenses falling to $3.1 million in Q2 2026 from $3.5 million in Q2 2025. This reduction was led by decreases in general and administrative expenses and stable research and development spending.

Research and development expenses remained flat at $1.2 million, with decreases in salaries and clinical trial costs offset by increased preclinical expenses focused on IND-enabling activities for the lead T-Cell Engager candidate, HCW11-018b. General and administrative expenses declined 11% to $1.9 million, driven by lower stock-based compensation and accretion expense on secured notes following a debt restructuring in May 2025.

What the Numbers Show

A critical divergence exists between the company’s operational performance and its reported bottom line. While operating losses narrowed slightly to $3.2 million from $3.5 million in the prior year quarter, the final net loss more than doubled. This indicates that the quarterly result was not driven by operational inefficiencies but rather by non-recurring accounting adjustments related to warrant liabilities and liability extinguishments. Investors should note that the core operational burn rate has stabilized despite the higher headline loss.

Clinical and Business Updates

HCW Biologics provided updates on its pipeline, highlighting preliminary human data for HCW9302, a fusion immunotherapeutic for autoimmune diseases. In a Phase 1 study for alopecia areata, all three participants in the second dose cohort showed preliminary improvements in Severity of Alopecia Tool scores, with no reported dose-limiting toxicities or capillary leak syndromes. The company remains on track for a full Phase 1 data readout in Q4 2026.

Additionally, the company re-acquired ex vivo rights to two commercial-ready molecules from AlloTera Therapeutics and is seeking partners to commercialize HCW9206 as a reagent for CAR-T therapy production. HCW Biologics also requested a Type B pre-IND meeting with the FDA for its T-cell engager candidate, HCW11-018b, targeting solid tumors.

Liquidity and Capital Structure

To support its operations, HCW Biologics raised approximately $5.6 million through two private placements in May and July 2026. These offerings included common stock, pre-funded warrants, and common warrants, with participation from officers and directors including CEO Hing C. Wong and Chairman Scott Garrett.

As of June 30, 2026, the company held $741,324 in cash and cash equivalents, down from $1.95 million at year-end 2025. Total current liabilities stood at $18.6 million, including $10.6 million in accounts payable. The company disclosed substantial doubt regarding its ability to continue as a going concern without additional funding, though it noted early success in its multi-step financing plan. HCW Biologics also regained compliance with Nasdaq’s bid price rule following a one-for-six reverse stock split effective June 30, 2026.

HCW Biologics Inc. (NASDAQ: HCWB) has priced a $1.6 million private placement offering to fund the advancement of its clinical-stage immunotherapeutics pipeline. The company agreed to sell 618,682 units to a group of investors that includes officers, directors, and an existing stockholder. The capital raise supports ongoing clinical trials for HCW9302 and IND-enabling studies for its T-Cell Engager, HCW11-018b, and second-generation immune checkpoint inhibitor, HCW11-040.

The transaction closes on July 29, 2026, subject to customary conditions. Each unit consists of one share of common stock or one pre-funded warrant, plus the right to receive one common stock purchase warrant upon stockholder approval. The purchase price was set at $2.585 per unit for those containing common stock and $2.5849 for those containing pre-funded warrants.

Offering Structure

The issuance comprises 218,682 shares of common stock and 400,000 pre-funded warrants. Investors are entitled to receive common warrants to purchase up to 618,682 shares, contingent on shareholder approval required under Nasdaq Listing Rule 5635(d).

Pre-funded warrants are exercisable immediately at $0.0001 per share and do not expire until fully exercised. Common warrants expire on the 5.5-year anniversary of their issuance.

Key Participants and Terms

Hing C. Wong, Ph.D., Founder and Chief Executive Officer; Scott Garrett, Chairman of the Board; and Lee Flowers, Senior Vice President of Business Development, participated in the offering on identical terms to other investors. No single investor may hold more than 9.99% of the company’s outstanding common stock after giving effect to the issuance and exercise of pre-funded warrants.

Regulatory Filings

On July 29, 2026, HCW Biologics entered into a registration rights agreement with the investors. The company will submit a Form S-1 registration statement to the U.S. Securities and Exchange Commission (SEC) within 15 trading days of closing. This filing covers the resale of common stock issued in the offering, shares issuable upon exercise of pre-funded warrants, and shares issuable upon exercise of common warrants. The company committed to using commercially reasonable efforts to have the statement declared effective within 60 days of closing.

What the Numbers Show

The reliance on insider participation from the CEO, Chairman, and SVP signals strong internal confidence in the valuation and future prospects of the pipeline. By structuring the deal with pre-funded warrants, the company maximized immediate cash inflow while deferring potential dilution from the common warrants until after stockholder approval is secured.